Compare Quest Diagnostics Inc (DGX) vs Eni SpA (E) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Eni SpA — how do they compare? Quest Diagnostics Inc trades at $205.09 (market cap $22.80B), while Eni SpA trades at $49.05 (market cap $71.95B). The key difference: Eni SpA is far larger — about 3.2× Quest Diagnostics Inc's market cap, and Eni SpA pays the higher dividend (4.93%). Which is the better fit depends on your goals.
| DGX | E | |
|---|---|---|
Market Cap | $22.80B | $71.95B |
Sector | Health | Energy |
52-Week High | $216.02 | $57.61 |
52-Week Low | $166.42 | $32.93 |
Enterprise Value | $28.82B | $90.86B |
Dividend Yield | 1.67% | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Eni (E) trades at $49.44, up 3.6% with a bullish technical signal supported by moving averages. The stock shows attractive valuation with P/E of 21.81 and P/S of 0.8, though revenue has declined from $132.5B in 2022 to $82.15B in 2025. Recent strategic moves include lithium investments in Chile, fusion energy partnerships, and global gas portfolio expansion. The company maintains positive cash flow with $238M net cash flow in 2025 and pays a $0.63 dividend.
Eni presents a mixed outlook with strong diversification efforts offset by declining revenue trends. The stock offers value characteristics with below-market valuations and dividend income, but faces headwinds from volatile energy markets and execution risks in new ventures. Analyst consensus leans cautious with 62% hold ratings, suggesting patience may be warranted despite current bullish technical momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
